Search Within

Advanced Practice Providers

  1. "Gastrointestinal Oncology Service"
Formats
  1. Meeting Abstract (72)
  2. Journal Article (59)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Miscellaneous (1)
  7. Review (1)
Groups
  1. Department of Medicine (137)
  2. Gastrointestinal Oncology Service (137)
  3. Solid Tumor Oncology Division (137)
  4. Nursing (115)
  5. Center for Pancreatic Cancer Research (62)
  6. Survivorship Research (55)

More Groups

People
  1. Ellen Hollywood (37)
  2. Leonard Saltz (31)
  3. Armin Shahrokni (30)
  4. Diane Reidy (28)
  5. Andrew Epstein (27)
  6. Beatriz Korc-Grodzicki (26)

More People

Years
  1. 2025 (4)
  2. 2024 (4)
  3. 2023 (6)
  4. 2022 (9)
  5. 2021 (14)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (56)
  2. Journal of Pain and Symptom Management (8)
  3. JCO Oncology Practice (7)
  4. Journal of the American Geriatrics Society (5)
  5. Annals of Oncology (4)
  6. Cancer (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. Elsevier Inc. (15)
  3. Wiley Blackwell (11)
  4. Oxford University Press (7)
  5. American Association for Cancer Research (5)
  6. Springer (4)

More Publishers

Results (137)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus Ipilimumab in advanced melanoma
    Journal Article

    Wolchok, J. D.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Rizvi, N. A.; Lesokhin, A. M.; Segal, N. H.; Ariyan, C. E.; Gordon, R. A.; Reed, K.; more...
    New England Journal of Medicine (2013)

    Fulltext@MSK | Save
  • 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial
    Meeting Abstract

    Drilon, A. E. D. C.; Kyuichi, K.; Huberman, K. H.; Sima, C. S.; Fiore, J. J.; Yu, H. A.; Varghese, A. M.; Sumner, D. K.; Travis, W. D.; Heguy, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer
    Meeting Abstract

    Cercek, A.; Shia, J. R.; Gollub, M.; Raasch, P. J.; Hollywood, E.; Reidy, D. L.; Janjigian, Y. Y.; Stadler, Z. K.; Segal, N. H.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
    Journal Article

    Reidy-Lagunes, D. L. ; Vakiani, E.; Segal, M. F.; Hollywood, E. M.; Tang, L. H.; Solit, D. B.; Pietanza, M. C.; Capanu, M.; Saltz, L. B.
    Cancer (2012)

    Fulltext@MSK | Save
  • Outcomes of patients undergoing percutaneous biliary drainage to reduce bilirubin for administration of chemotherapy
    Journal Article

    Thornton, R. H.; Ulrich, R.; Hsu, M.; Moskowitz, C.; Reidy-Lagunes, D.; Covey, A. M.; Brody, L. A.; Robson, P. M.; Sofocleous, C. T.; Solomon, S. B.; more...
    Journal of Vascular and Interventional Radiology (2012)

    Fulltext@MSK | Save
  • Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors
    Journal Article

    Chung, K. Y.; Saito, K.; Zergebel, C.; Hollywood, E.; Segal, M.; Saltz, L. B.
    Oncology (2011)

    Fulltext@MSK | Save
  • A phase II clinical T trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R) in patients with metastatic well differentiated neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy, D. L.; Hollywood, E.; Segal, M.; Saltz, L.
    Pancreas (2011)

    Fulltext@MSK | Save
  • A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy, D. L.; Hollywood, E.; Segal, M.; Saltz, L.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    Journal Article

    Reidy, D. L.; Vakiani, E.; Fakih, M. G.; Saif, M. W.; Hecht, J. R.; Goodman-Davis, N.; Hollywood, E.; Shia, J. R.; Schwartz, J.; Chandrawansa, K.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study)
    Journal Article

    Zhang, W.; Azuma, M.; Lurje, G.; Gordon, M. A.; Yang, D.; Pohl, A.; Ning, Y.; Bohanes, P.; Gerger, A.; Winder, T.; more...
    Anticancer Research (2010)

    Fulltext@MSK | Save